Logo_Schriftzug_schwarz_gedrehtLogo_Schriftzug_schwarz_gedrehtLogo_Schriftzug_schwarz_gedrehtLogo_Schriftzug_schwarz_gedreht
  • Home
  • Aktuell
  • Archiv
  • Editorial
  • Kontakt
✕
Inhibition of mTOR with everolimus for the treatment of advanced renal cell carcinoma after failure of anti-VEGF therapy
2. Februar 2021
Ranolazin: Effektiv bei makro- und mikrovaskulär verursachten Angina pectoris Beschwerden durch direkte Wirkung im ischämischen Myocard
2. Februar 2021
Weilersbach N mit Kommentar von Rieckmann P

Long-term benefit of early multiple sclerosis treatment with interferon beta-1b: lower disease activity, delayed disability progression, improved overall survival

J Med Drug Rev 2012;2;31-39
(Review-Artikel in deutscher Sprache)

Multiple sclerosis (MS) often starts in early adulthood und thereafter typically takes a course over several decades. However, clinical studies in MS with usual treatment periods of one to three years cover this long-term course only inadequately. In contrast to this, the clinical development program of betaferon® (interferon-beta-1b, IFNβ-1b) paid special attention to the long-term follow-up of patients even after the termination of the pivotal clinical studies.

To gain marketing admission for IFNβ-1b, three large placebo-controlled studies were conducted: a) in patients with relapsing-remittent MS (RRMS), b) in patients with clinically isolated syndromes (CIS), and c) in patients with secondary progressive MS (SPMS). 8-year follow-up data are available for the CIS and SPMS studies. Regarding the RRMS study, efficacy and safety of IFNβ-1b treatment were analysed after 16 years and mortality data were collected after 21 years.

The 8-year follow-up study demonstrated the benefit of early IFNβ-1b treatment (within 60 days after CIS onset) by a lower incidence of clinical definitive MS (CDMS) compared with delayed treatment (the group originally receiving placebo; 55.5% vs. 65.8%). Additionally, a lower relapse rate was observed during the whole 8-year period (0.20 vs. 0.26 annually). In SPMS patients, early IFNβ-1b treatment significantly delayed the disability progression over 6 years; the 8-year data still show a strong trend regarding this parameter.

16-year data: Early IFNβ-1b treatment of RRMS (250 µg subcutaneously every other day) is effective and delays disability progression according to a correlative model. Additionally, 21-year data demonstrate a significant mortality reduction by almost half compared with the group originally receiving placebo (hazard ratio: 0.532, 95 % CI: 0.314-0.902, P=0.0137).

Conclusions
The methodically carefully designed and performed long-term follow-ups in MS patients confirm the maintained benefit of early IFNβ-1b treatment even after 8, 16, and 21 years.
JMDR_Betaferon_2012Web

Ähnliche Beiträge

7. Juli 2021

Trastuzumab-Deruxtecan beim HER2-positiven metastasierten Mammakarzinom


Zum Artikel
3. Februar 2021

Von der Glucosereduktion zur Behandlung der Herzinsuffizienz


Zum Artikel
3. Februar 2021

Gynäkologische Anwendungen von Dienogest alleine und in Kombination mit Östrogenen


Zum Artikel

Kontakt

Herausgeber
Reprint Publications GmbH & Co. KG
Seeshaupter Str. 85
82541 Münsing

Tel.: +49 (0) 8801-913149-0
Email: diz@jmdrev.online
Web: www.jmdrev.online
Web: www.reprint-publications.com


in Zusammenarbeit mit
PharmKomm
Grüner Weg 6
52349 Düren

Tel.: +49 (0) 2421-99469-39
Email: dab@jmdrev.online
Web: www.jmdrev.online
Web: www.pharmkomm.de

© 2022 Journal of Medical Drug Reviews      Impressum | Datenschutz | Cookie-Einstellungen